Jack W. Reich
General Counsel bei ADIAL PHARMACEUTICALS, INC.
Profil
Jack W.
Reich is the founder of SICOR, Inc., Collateral Therapeutics, Inc., Chiron Viagene, Inc., Renova Therapeutics, Inc. He is currently the Head of Regulatory Affairs at Adial Pharmaceuticals, Inc.
Aktive Positionen von Jack W. Reich
Unternehmen | Position | Beginn |
---|---|---|
ADIAL PHARMACEUTICALS, INC. | General Counsel | 14.12.2020 |
Ehemalige bekannte Positionen von Jack W. Reich
Unternehmen | Position | Ende |
---|---|---|
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Vorstandsvorsitzender | - |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | Gründer | - |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Gründer | - |
Renova Therapeutics, Inc.
Renova Therapeutics, Inc. BiotechnologyHealth Technology Renova Therapeutics, Inc. operates as a biopharmaceutical company. The firm is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. Its product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in patients with CHF. The company was founded by Jack W. Reich, H. Kirk Hammond and Craig Andrews in 2009 and is headquartered in San Diego, CA. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ADIAL PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Renova Therapeutics, Inc.
Renova Therapeutics, Inc. BiotechnologyHealth Technology Renova Therapeutics, Inc. operates as a biopharmaceutical company. The firm is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. Its product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in patients with CHF. The company was founded by Jack W. Reich, H. Kirk Hammond and Craig Andrews in 2009 and is headquartered in San Diego, CA. | Health Technology |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | Health Technology |
Chiron Viagene, Inc.
Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Commercial Services |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Commercial Services |